As a participant of the upcoming symposium “2nd GCCIR Matchmaking Symposium” organized by Innoget and GCCIR next November 25th, 2019 in Barcelona (Spain), the company 48Hour Discovery Inc. is seeking European partners to meet at the Barcelona event to develop a joint collaboration project.
48Hour Discovery Inc. is specifically interested in European partners with expertise in drug discovery technologies and a focus on precision medicine. Further details are described below.
In case you are interested in meeting 48Hour Discovery Inc. in Barcelona to discuss a potential collaboration, please register for free to the symposium clicking the “Register to the symposium” button above.
48Hour Discovery Inc. is a biotechnology company specializing in peptide derived therapeutics and drug discovery for global healthcare companies. Its novel, patented serum and GI-stable peptide macrocycles enable discovery collaborations (service agreements), annual subscriptions of services and non-exclusive technology transfer partnerships (licensing agreements) with leading pharmaceutical companies and research institutions.
48HD’s advanced discovery platform is based on proprietary linkers, billion scale genetic encoded libraries, a streamlined workflow and open-access data management. The platform enables the rapid identification of highly effective hit candidates, which exhibit excellent selectivity and gastrointestinal stability for oral delivery.
The company is participating in this mission to search for partners that have drug discovery related technologies such as protein scaffolds, macrocycle technologies, or other post-translational modifications and for companies or research institutes conducting clinical trials with a focus on precision medicine.
Preferences / Requirements for Potential European Partner(s)
The following are the important aspects 48Hour Discovery Inc. is looking for in a European partner:
- Expertise in drug discovery
- Expertise in chemistry
- Expertise in drug candidate validation assays
- Expertise in clinical trials